Ritholtz Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.57M Buy
405,562
+42,506
+12% +$678K 0.09% 148
2026
Q2
$6.16M Buy
363,056
+48,630
+15% +$777K 0.09% 135
2026
Q1
$4.66M Buy
314,426
+55,610
+21% +$813K 0.08% 178
2025
Q4
$4.13M Buy
258,816
+174,301
+206% +$2.47M 0.08% 183
2025
Q3
$934K Buy
+84,515
New +$923K 0.02% 519

Other funds holding AUPH

Ritholtz Wealth Management's AUPH Position: Q3 2026 in Review

Ritholtz Wealth Management increased its Aurinia Pharmaceuticals (AUPH) stake by 12% in Q3 2026, buying an estimated $678K and bringing the position to 405,562 shares worth $6.57M. The position accounts for 0.09% of the portfolio, ranked #148.

Ritholtz Wealth Management first reported a position in AUPH in Q3 2025 and has held it in 5 quarters since. 182 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Ritholtz Wealth Management held 405,562 shares of Aurinia Pharmaceuticals worth $6.57M as of Q3 2026.
  • Ritholtz Wealth Management bought 42,506 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $678K.
  • Aurinia Pharmaceuticals made up 0.09% of Ritholtz Wealth Management's portfolio in Q3 2026, its #148 holding.
  • Ritholtz Wealth Management first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 182 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Ritholtz Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.